Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (13546)	7/15/2004 2:00:26 AM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

<font color=red>Dimethaid receives negative results for WF10 study 2004-07-14 17:14 ET - News Release Ms. Rebecca Keeler reports DIMETHAID REPORTS NEGATIVE RESULTS FOR PHASE III HIV/AIDS STUDY Dimethaid Research Inc. has completed initial analysis of data from a phase III study showing that immune regulating drug, WF10, failed to meet primary end points. An independent statistician, appointed by Oxo Chemie AG, has confirmed Dimethaid's analysis. The study, conducted in 229 late-stage HIV/AIDS patients at 32 sites across the United States and Canada, indicated no statistical difference between WF10 and placebo in affecting the time to onset of clinical progression, defined as any new AIDS-defining event or death. "Although this study raises questions about WF10 as an AIDS treatment, we have always believed, and still believe, the drug has potential in autoimmune diseases and oncology," said Rebecca E. Keeler, president and chief executive officer. "However, given these results and the financial pressures resulting from recent dissident shareholder actions, the company will not proceed with additional WF10 development at this time." The randomized, double-blinded, placebo-controlled, 96-week study designed by Oxo was limited to late-stage AIDS patients with CD4-plus counts below 50 cells per cubic millilitre of blood. The last patient completed the trial in September, 2001, prior to Dimethaid's acquisition of the Swiss-based company. A contract research organization, hired by Oxo to conduct the trial and collect patient information, transferred final data and case report forms to Dimethaid between March, 2004, and May, 2004. Dimethaid then completed the compilation of new AIDS-defining events with an independent end-point committee before breaking the randomization code. Previous WF10 clinical studies, conducted between 1993 and 1996, established the safe dosing range and investigated the immunological changes resulting from WF10 treatment. In 1995, a placebo-controlled phase II trial with 19 late-stage AIDS patients at Vanderbilt University showed a statistically significant improvement in survival, along with fewer hospitalizations and deaths. Over the next few weeks, Dimethaid will continue to analyze the most recent study's secondary end points, which include the number and duration of hospitalizations, as well as the density of CD38-plus antigen markers on CD8 T-cells. Dimethaid will also re-evaluate WF10's future business potential and its position in the company's long-term development pipeline. WARNING: The company relies upon litigation protection for "forward-looking" statements.